Stock Market News
Amryt Pharma signs fifth distribution agreement in three months
Biopharmaceutical company Amryt Pharma announced further expansion in the Middle East on Tuesday, with a new distribution agreement.
Phareon Healthcare will handle distribution in Lebanon, Syria and Jordan of Amryt's Lojuxta product, which is a therapy used for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH).
Joe Wiley, chief executive of Amryt Pharma, said: "Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians' requests regarding their patients suffering with HoFH."
HoFH is a rare, life threatening genetic cholesterol disorder which Amryt estimates will affect approximately 40 patients in the countries covered by the agreement.
"This is Amryt's fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria," said Wiley.
AIM-traded Amryt holds an exclusive licence to sell Lojuxta across the European Economic Area, Middle East and North Africa, Turkey and Israel through distribution agreements with GryNumber Health, Romastru Trading, RCC Pharma and Faisal Musaed El Seif Saudi Pharmaceutical Company.
As of 0817 GMT, Amryt Pharma's shares were up 3.11% at 19.08p.
Phareon Healthcare will handle distribution in Lebanon, Syria and Jordan of Amryt's Lojuxta product, which is a therapy used for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH).
Joe Wiley, chief executive of Amryt Pharma, said: "Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians' requests regarding their patients suffering with HoFH."
HoFH is a rare, life threatening genetic cholesterol disorder which Amryt estimates will affect approximately 40 patients in the countries covered by the agreement.
"This is Amryt's fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria," said Wiley.
AIM-traded Amryt holds an exclusive licence to sell Lojuxta across the European Economic Area, Middle East and North Africa, Turkey and Israel through distribution agreements with GryNumber Health, Romastru Trading, RCC Pharma and Faisal Musaed El Seif Saudi Pharmaceutical Company.
As of 0817 GMT, Amryt Pharma's shares were up 3.11% at 19.08p.
Related share prices |
---|
Amryt Pharma (AMYT) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price